Bulletin or noticeIn effectUtahAlabama

States split on the HHS peptide policy: Utah follows it, medical boards are told it changes no state law

The day HHS published its peptide enforcement policy, Utah said it would match it. On November 10 the Federation of State Medical Boards told boards the opposite lesson: federal non enforcement does not amend state law or board authority.

Source Oct 30, 2026Briefing Nov 15, 2026Reviewed Nov 15, 2026Next review Jan 15, 2027
01What changed

On October 30, 2026 Utah's Division of Professional Licensing said it will exercise similar limited enforcement discretion in Utah, in strict accordance with the scope of the HHS interim policy, and only when each HHS condition is met.

On November 10 the Alabama Board of Medical Examiners published an FSMB FAQ on the same policy. It says the policy does not amend state practice acts or direct boards to suspend enforcement; that a state requirement of 503A compliance should not be treated as met just because a compounder follows the HHS policy; that physicians who compound face the same conditions as pharmacies; and that the policy names no state recipient, deadline or process for the reports it requires. It lists the Alabama, Mississippi and South Carolina research grade peptide notices as current board positions.

02Who this affects
  • Pharmacies compounding any of the six peptides for patients in Utah or Alabama.
  • Nonresident pharmacies shipping peptides into states that have not spoken.
  • Prescribers and telehealth programs relying on the federal policy alone.

Utah's position covers Utah licensees. The FSMB FAQ is guidance to medical boards, not a rule, but it sets out how boards are being told to read the federal policy. Other states have not yet said where they stand.

03Key dates
Source publishedOctober 30, 2026Utah DOPL announcement.
Source publishedNovember 10, 2026FSMB FAQ dated November 10, published by the Alabama Board of Medical Examiners.
04Why it matters

The federal policy only answers the federal question. Each state now decides for itself, and the early answers point in opposite directions. Until a state speaks, the safer reading is that its existing law and board notices still apply.

05What to do now
  1. List every state you ship peptides into and record its current position, with a link to the source.
  2. Treat states with research grade peptide notices as unchanged unless the board says otherwise in writing.
  3. Ask each board how it wants the policy's state reports delivered, and keep the answer.
06How this relates to certification

Licensure and Registration. The Licensure and Registration domain covers the state permits and board requirements a shipping pharmacy must meet. Peptide compounding now depends on each state's own position as well as the federal policy.

07Sources
All briefingsRevision 2ebe888be508

Know where your pharmacy stands before the rules change again.

Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.

Back to Regulatory Watch